

Xcopri - (12.5, 25, 50, 100, 150 and 200 mg ; Tablet)

Generic Name	Cenobamate	Innovator	SK Life
Dosage	12.5, 25, 50, 100, 150 and 200 mg ; Tablet	Branded US Sales	Less Than \$1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	Less Than 5
Other ANDA developers	Less Than 5	Tentative Approvals	None
Final Approvals	None	Generic Launches	None
Indication	XCOPRI is indicated for the treatment of partial-onset seizures in adult patients.		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.